MA32013B1 - Derives de l'acide phenylacetique utiles comme modulateurs de l'inflammation - Google Patents

Derives de l'acide phenylacetique utiles comme modulateurs de l'inflammation

Info

Publication number
MA32013B1
MA32013B1 MA33012A MA33012A MA32013B1 MA 32013 B1 MA32013 B1 MA 32013B1 MA 33012 A MA33012 A MA 33012A MA 33012 A MA33012 A MA 33012A MA 32013 B1 MA32013 B1 MA 32013B1
Authority
MA
Morocco
Prior art keywords
inflammation
acid derivatives
phenylacetic acid
modulating agent
cycloalkyl
Prior art date
Application number
MA33012A
Other languages
Arabic (ar)
English (en)
Inventor
Mark Grillo
An-Rong Li
Jiwen Liu
Julio C Medina
Yongli Su
Yingcai Wang
Janan Jona
Alan Allgeier
Jacqueline Milne
Jerry Murry
Joseph F Payack
Thomas Storz
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA32013B1 publication Critical patent/MA32013B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La présente invention concerne des composés, des compositions pharmaceutiques et des procédés utiles dans le traitement de maladies et d'états inflammatoires et du système immunitaire. En particulier, l'invention concerne des composés modulateurs de la fonction et/ou de l'expression de protéines impliquées dans des maladies atopiques, des états inflammatoires et le cancer. Les composés selon l'invention sont des dérivés de l'acide carboxylique de formule i dans laquelle r1 est alkyle ou cycloalkyle; r2 est halo, alkyle, haloalkyle, alcoxy, haloalcoxy ou cycloalkyle; et x est chloro ou fluoro.
MA33012A 2007-12-19 2010-07-14 Derives de l'acide phenylacetique utiles comme modulateurs de l'inflammation MA32013B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US843307P 2007-12-19 2007-12-19
PCT/US2008/013833 WO2009085177A1 (fr) 2007-12-19 2008-12-18 Dérivés de l'acide phénylacétique utiles comme modulateurs de l'inflammation

Publications (1)

Publication Number Publication Date
MA32013B1 true MA32013B1 (fr) 2011-01-03

Family

ID=40564868

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33012A MA32013B1 (fr) 2007-12-19 2010-07-14 Derives de l'acide phenylacetique utiles comme modulateurs de l'inflammation

Country Status (20)

Country Link
US (1) US8183293B2 (fr)
EP (1) EP2231595B1 (fr)
JP (1) JP5437267B2 (fr)
KR (1) KR20100102668A (fr)
CN (1) CN101903338A (fr)
AR (1) AR071279A1 (fr)
AU (1) AU2008343924B2 (fr)
BR (1) BRPI0821197A2 (fr)
CA (1) CA2707789A1 (fr)
CL (1) CL2008003832A1 (fr)
CO (1) CO6321234A2 (fr)
CR (1) CR11572A (fr)
EA (1) EA201001029A1 (fr)
ES (1) ES2471919T3 (fr)
IL (1) IL206069A0 (fr)
MA (1) MA32013B1 (fr)
PE (1) PE20091526A1 (fr)
TN (1) TN2010000223A1 (fr)
TW (1) TW200940051A (fr)
WO (1) WO2009085177A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
US9974759B2 (en) * 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension
US20180021302A1 (en) * 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
MX2018011453A (es) 2016-03-22 2019-01-10 Merck Sharp & Dohme Moduladores alostericos de receptores de acetilcolina nicotinicos.
EP3424927B1 (fr) * 2017-07-04 2019-04-17 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Procédé efficace de préparation de la sitagliptine au moyen d'une très efficace préparation d'acide 2,4,5-trifluorophenylacétique intermédiaire

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704158D0 (en) 1987-02-23 1987-04-01 Wellcome Found Substituted hydantoin compounds
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
AU7006094A (en) 1993-06-30 1995-01-24 Wellcome Foundation Limited, The Anti-atherosclerotic diaryl compounds
US5545669A (en) * 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
AU695255B2 (en) * 1994-12-20 1998-08-13 F. Hoffmann-La Roche Ag Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
CZ86199A3 (cs) 1996-09-12 1999-08-11 Schering Aktiengesellschaft Benzamidinové deriváty substituované cyklickou aminokyselinou a cyklické hydrokyselinové deriváty, farmaceutický prostředek obsahující tyto látky a jejich použití jako protisrážecích činidel
US6008234A (en) * 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
JPH11202458A (ja) 1998-01-16 1999-07-30 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US5929250A (en) 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
AU3665199A (en) 1998-04-29 1999-11-16 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AR023659A1 (es) 1998-09-18 2002-09-04 Vertex Pharma Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
HUP0200248A3 (en) 1999-03-01 2002-11-28 Pfizer Prod Inc Oxamic acids and derivatives as thyroid receptor ligands, pharmaceutical compositions containing them as active ingredient and their use
JP3828364B2 (ja) 1999-03-10 2006-10-04 塩野義製薬株式会社 ［２．２．１］および［３．１．１］ビシクロ骨格を有するｐｇｄ２／ｔｘａ２両受容体拮抗性医薬組成物
AU772121B2 (en) 1999-08-23 2004-04-08 Bml, Inc. Method of identifying properties of substance to prostaglandin D receptors
US6531291B1 (en) * 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
US20020072530A1 (en) 2000-02-01 2002-06-13 Bing-Yan Zhu Indole and benzimidazole inhibitors of factor Xa
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
EP1295872A4 (fr) 2000-06-02 2007-05-16 Shionogi & Co Composition medicamenteuse antagoniste pour les recepteurs de pgd2/txa2
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
AU2002229611A1 (en) 2000-12-08 2002-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells
JP2004517851A (ja) 2000-12-27 2004-06-17 バイエル アクチェンゲゼルシャフト 甲状腺受容体のリガンドとしてのインドール誘導体
JP4279561B2 (ja) 2001-05-23 2009-06-17 メルク フロスト カナダ リミテツド プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体
JP4529119B2 (ja) 2001-08-09 2010-08-25 小野薬品工業株式会社 カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003221325A1 (en) 2002-03-19 2003-09-29 Ono Pharmaceutical Co., Ltd. Carboxyoic acid compounds and drugs containing the compounds as the acive ingredient
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
AU2003231513A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
MXPA05006701A (es) * 2002-12-20 2006-03-30 Amgen Inc Moduladores de asma y de inflacion alergica.
ES2299906T3 (es) 2003-11-25 2008-06-01 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisomas.
US8148572B2 (en) * 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
NZ577109A (en) * 2006-12-15 2011-12-22 Glaxo Group Ltd Benzamide derivatives as ep4 receptor agonists
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
KR20120046762A (ko) 2009-07-31 2012-05-10 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 피부 제형
WO2011014587A2 (fr) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Compositions pharmaceutiques ophtalmiques d'antagonsites du récepteur dp2

Also Published As

Publication number Publication date
CO6321234A2 (es) 2011-09-20
TW200940051A (en) 2009-10-01
AR071279A1 (es) 2010-06-09
KR20100102668A (ko) 2010-09-24
BRPI0821197A2 (pt) 2015-06-16
CA2707789A1 (fr) 2009-07-09
WO2009085177A1 (fr) 2009-07-09
EP2231595B1 (fr) 2014-04-23
TN2010000223A1 (en) 2011-11-11
US8183293B2 (en) 2012-05-22
ES2471919T3 (es) 2014-06-27
JP2011507847A (ja) 2011-03-10
JP5437267B2 (ja) 2014-03-12
CR11572A (es) 2010-08-13
IL206069A0 (en) 2010-11-30
US20090275659A1 (en) 2009-11-05
PE20091526A1 (es) 2009-11-01
AU2008343924B2 (en) 2013-01-17
EA201001029A1 (ru) 2011-06-30
EP2231595A1 (fr) 2010-09-29
AU2008343924A2 (en) 2011-02-17
AU2008343924A1 (en) 2009-07-09
CN101903338A (zh) 2010-12-01
CL2008003832A1 (es) 2010-03-26

Similar Documents

Publication Publication Date Title
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA32013B1 (fr) Derives de l'acide phenylacetique utiles comme modulateurs de l'inflammation
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
EP4331668A3 (fr) Composés pour inhiber nlrp3 et leurs utilisations
MA35576B1 (fr) Nouveaux composés
TN2009000138A1 (fr) Biaryl-ether-urees
MA41238A (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA28077A1 (fr) Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
ATE538099T1 (de) 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden
MA33987B1 (fr) Bloqueurs de canaux sodiques sensibles au potentiel
CY1110969T1 (el) 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
TN2012000192A1 (fr) N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase
MA29330B1 (fr) Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires.
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MX2008012404A (es) Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g.
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit